We aimed to summarize evidence from and assess the quality of published quantitative systematic reviews evaluating the cancer risk associated with SGLT‐2 inhibitor use in the treatment of type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.